This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Type of economic evaluation
Cost-utility analysis
Study objective
The objective of the study was to develop a decision analytic model evaluating the cost-effectiveness of bisphosphonates in comparison with no treatment for postmenopausal women, using individual estimates for the risks of fracture. The sub-group analyses (20 sub-groups determined from age and clinical risk factors) represented the key aspect of the economic evaluation.
Interventions
The study examined 5-year therapy with bisphosphonates (risedronate and alendronate) in postmenopausal women. This was compared with a strategy of no treatment.
Location/setting
UK/primary care.
Methods

Analytical approach:
A decision analytic model was constructed in order to determine the clinical and economic impact of bisphosphonate use over no treatment in different cohorts of women defined by age and risk factors. The model was populated on the basis of individual risk factors. The time horizon of the analysis was 10 years. The perspective of the analysis was not explicitly stated.
Effectiveness data:
The primary sources used to derive clinical estimates were based on a selection of known relevant studies. Fracture risks (hip, vertebral, wrist, humerus) were derived from the Health Improvement Network research database, which uses data gathered by general practitioners (GPs) in a very large cohort of UK women aged 50 to 100. Risk factors were selected on the basis of data derived from a large meta-analysis of prospective epidemiological studies. Other variables were based on a large report, the European Prospective Osteoporosis Study. However, the key clinical estimate was the fracture risk reduction due to bisphosphonates, which was obtained from a published health technology assessment (HTA) issued by the National Institute for Clinical Excellence (NICE). Equal efficacy was assumed for alendronate and risedronate.
Monetary benefit and utility valuations:
Utility estimates were based on a NICE HTA that used age-specific EuroQol (EQ-5D) utilities. 
Measure of benefit:
The summary benefit measure used was the quality-adjusted life-years (QALYs). These were estimated using the decision model. An annual discount rate of 1.5% was applied.
Cost data:
The categories of costs included in the analysis were bisphosphonate prescriptions, bone mineral density measurement, GP visits and services related to the treatment of fractures. The costs and quantities were based on a publication by NICE and were reported as macro-categories. The costs were discounted at an annual rate of 6%. The costs were in UK pounds sterling (£). The price year was not reported.
Analysis of uncertainty:
Several univariate sensitivity analyses were performed in order to determine the threshold values of key model inputs at which the results of the base-case analysis would change. Bootstrapping was conducted to obtain confidence intervals (CIs) around mean estimates.
Results
The expected costs and QALYs were not reported.
In general, the cost-effectiveness analysis showed that the incremental cost per QALY gained with bisphosphonates was better (i.e. lower) for elderly women and in women with a history of fracture. For example, the ratio was £8,000 in women aged at least 90 years without fracture history (£17,000 for women with low baseline fracture risk and £4,000 for women with high baseline fracture risk). The ratio was £38,000 in women aged 50 to 59 years and older with a fracture history (£58,000 for women with low baseline fracture risk and £35,000 for women with high baseline fracture risk).
Using a cost-acceptability ratio of £30,000 per QALY gained, bisphosphonate treatment became cost-effective for patients with a 5-year risk of 9.3% (95% CI: 8.0 to 10.5) for osteoporotic fractures and 2.1% (95% CI: 1.5 to 2.7) for hip fractures.
When bone mineral density was included in the risk assessment, the cost per QALY gained was £35,000 in women at age 60 with a fracture history and a T-score of -2.5, and £3,000 at age 80.
The results of the sensitivity analysis confirmed the robustness of the base-case results. In general, the key finding of the analysis was that the cost-effectiveness of bisphosphonates was dramatically dependent on risk factors and characteristics such as age, body mass index, early menopause and baseline T-score.
